Posts tagged “Chimerix ”
In today's wrapup of news about the Triangle tech community from other publications: Move Loot ceases operations in Durham and elsewhere; a smallpox vaccine is the hope for Chimerix; Icagen raises $1.5 million; and the latest on Charles Hayes-NCSU.
In today's wrapup of Triangle tech and life science news: Chimerix says antiviral didn't improve survival rates; Cary-based Chiesi USA buys cardiovascular products; and Durham-based Measurement, Inc. loses a big contract.
Failure of a potential transplant treatment in a late-stage clinical trial triggered more than an 80 percent plunge in the price of Chimerix shares two months ago. The Durham drug development firm on Monday disclosed it had slashed its work force by 20 percent and also was cutting R&D spending.
CH joins Smart City effort; Cree rallies on upgrade; Chimerix stock plunges; Uber driver in shooting; Facebook Messenger update
In today's Bulldog wrapup of tech and life science news: Chapel Hill joins AT&T Smart City initiative; analyst's upgrade sends Cree shares up; Chimerix shares plunge on bad clinical trial news; Uber says one of its drivers was involved in the Michigan shootings; and Facebook updates Messenger.
Chimerix, which has a contract potentially worth more than $400 million in the development of a first vaccine targeting smallpox, reports progress in development of an antiviral. In recent tests, its brincidofovir successfully treated 100 percent of animals infected with rabbitpox.
After a big drug trial failure and an 80 percent collapse of its stock on Monday, Durham-based drug firm Chimerix was basically written off by numerous analysts. But Chimerix is far from dead, especially after a big investment from Point72, a major Wall Street hedge fund.
Some big Wall Street analysts downgraded Chimerix on Tuesday after Monday's big drug trial failure news that triggered an 81 percent drop in its shares. But investors weren't all scared away as buying drove up Chimerix by more than 11 percent in heavy trading.
Failure of its lead drug in a Stage 3 clinical trial led to a fiscal bloodbath and a tsunami of bad publicity Monday for Durham-based Chimerix. A darling of investors and a company once seen as developing a cure for Ebola, the firm's stock "crater" by more than 81%.
30-minute delivery by drone?; Chimerix raises $175M; new BIO name; chips squeeze biz; Facebook's new app
In today's Bulldog wrapup of tech and life science news: Amazon foresees delivery by drones in 30 minutes; Chimerix raises $175 million in stock sale; a new name for BIO organization; new chips squeeze small businesses; and Facebook unveils new photo app.
Chimerix raising $150M; Jawbone-Fitbit fight; Spotify tunes up with $115M; Tesla's SUV coming; TransEnterix raising money
In today's Bulldog wrapup of technology and life science news: Durham-based Chimerix looks to raise $150 million for drug development; Jawbone sues Fitbit - again; Spotify raises $115 million to fight Apple; Tesla's SUV is coming soon; and RTP-based TransEnterix looks to raise money for robotic surgery system.
Drug giant GlaxoSmithKline is shipping the first few hundred doses of its vaccine that is being tested as a treatment for Ebola to Africa for further testing. GSK will soon begin testing the vaccine for efficacy. Currently there is no successful treatment for the deadly disease.
RTP-based BioCryst Pharmaceuticals is launching a clinical trial of a potential treatment for Ebola with funding support from the U.S. government. Durham-based Chimerix and GSK also are involved in the Ebola battle.
Even as backers pledged $390 million for Ebola vaccines, Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. It's not the vaccine being tested by GlaxoSmithKline.
Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.
The Ebola outbreak isn't generating big headlines in the U.S. these days, but forthcoming layoffs at GlaxoSmithKline are a hot topic. Unfortunately for GSK, the job cuts have overshadowed the company's progress in developing the first vaccine for the deadly Ebola.
Billionaire Bill Gates and his foundation are providing financial support to Durham-based Chimerix, helping it ramp up production of a potential vaccine for the deadly Ebola virus.